<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2021.11942</article-id>
<article-id pub-id-type="publisher-id">MMR-0-0-11942</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>miR-875-5p regulates IR and inflammation via targeting TXNRD1 in gestational diabetes rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Fu</surname><given-names>Songbo</given-names></name>
<xref rid="af1-mmr-0-0-11942" ref-type="aff">1</xref>
<xref rid="c1-mmr-0-0-11942" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Fu</surname><given-names>Songquan</given-names></name>
<xref rid="af2-mmr-0-0-11942" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Ma</surname><given-names>Xiaoni</given-names></name>
<xref rid="af1-mmr-0-0-11942" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xiaomei</given-names></name>
<xref rid="af1-mmr-0-0-11942" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Ling</surname><given-names>Jizu</given-names></name>
<xref rid="af3-mmr-0-0-11942" ref-type="aff">3</xref></contrib>
</contrib-group>
<aff id="af1-mmr-0-0-11942"><label>1</label>Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China</aff>
<aff id="af2-mmr-0-0-11942"><label>2</label>Department of Respiration, The First Hospital of Lanzhou City, Lanzhou, Gansu 730050, P.R. China</aff>
<aff id="af3-mmr-0-0-11942"><label>3</label>Department of Pediatrics, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-0-0-11942"><italic>Correspondence to</italic>: Dr Songbo Fu, Department of Endocrinology, The First Hospital of Lanzhou University, 1 Donggangxi Road, Chengguan, Lanzhou, Gansu 730000, P.R. China, E-mail: <email>songbofu123@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>05</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>25</day>
<month>02</month>
<year>2021</year></pub-date>
<volume>23</volume>
<issue>5</issue>
<elocation-id>303</elocation-id>
<history>
<date date-type="received"><day>28</day><month>05</month><year>2020</year></date>
<date date-type="accepted"><day>07</day><month>01</month><year>2021</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Fu et al.</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Gestational diabetes mellitus (GDM) is a serious life-threatening disease that affects the mother and fetus. However, the pathogenesis of GDM is still unclear. microRNAs (miRs) play vital roles in the regulation of various cell functions. The present study aimed to investigate the effects of miR-875-5p and thioredoxin reductase 1 cytoplasmic (TXNRD1) in GDM rats and analyze the associated underlying mechanism. A GDM rat model was induced using an intraperitoneal injection of streptozotocin. miR-875-5p knockdown plasmids or TXNRD1 knockdown plasmids were injected into the rats via the caudal vein. miR-875-5p and TXNRD1 expression in the serum were detected using reverse transcription-quantitative PCR (RT-qPCR) or western blot (WB) analyses. The fasting blood-glucose (FBG), fasting serum insulin, triglyceride and high density lipoprotein levels were detected by specific commercial kits. The inflammatory response and the induction of oxidative stress were analyzed by assessing the expression of associated markers via WB, RT-qPCR or commercial kits. The pancreatic and placental injuries were detected by hematoxylin and eosin staining. The results indicated that miR-875-5p expression levels were downregulated, whereas TXNRD1 levels were upregulated in GDM rats compared with normal pregnancy rats. miR-875-5p significantly regulated TXNRD1 expression in GDM rats. miR-875-5p silencing notably reduced FBG and insulin resistance, which was accompanied by reduced expression levels of blood lipid and pro-inflammatory markers as well as reduced oxidative stress. However, the effects of miR-875-5p could be reversed by TXNRD1 silencing. Therefore, the present study indicated that miR-875-5p regulated IR and inflammation by targeting TXNRD1 in GDM rats. miR-875-5p and TXNRD1 may be considered as potential targets for treating GDM.</p>
</abstract>
<kwd-group>
<kwd>gestational diabetes mellitus</kwd>
<kwd>microRNA-875-5p</kwd>
<kwd>thioredoxin reductase 1 cytoplasmic</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>First Hospital of Lanzhou University</funding-source>
<award-id>ldyyyn2018-59</award-id>
</award-group>
<award-group>
<funding-source>Research Fund Project of the Science and Technology Development Guiding Plan of Lanzhou City</funding-source>
<award-id>2019-ZD-38</award-id>
</award-group>
<award-group>
<funding-source>Construction of Gansu Province Clinical Research Center for Endocrine disease</funding-source>
<award-id>20JR10FA667</award-id>
</award-group>
<award-group>
<funding-source>Special Funds of Science and Technology Development of the Chinese Central Government</funding-source>
</award-group>
<funding-statement>The present study was supported by the Research Fund Project of the First Hospital of Lanzhou University (grant no. ldyyyn2018-59), the Research Fund Project of the Science and Technology Development Guiding Plan of Lanzhou City (grant no. 2019-ZD-38), Construction of Gansu Province Clinical Research Center for Endocrine disease (grant no. 20JR10FA667) and the Special Funds of Science and Technology Development of the Chinese Central Government to Guide Local in 2020 (an innovation platform for improving the prevention and treatment of frequently-occurring diseases in Gansu Province).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Gestational diabetes mellitus (GDM) is one of the common complications noted in the perioperative period, which affects normal glucose metabolism before pregnancy (<xref rid="b1-mmr-0-0-11942" ref-type="bibr">1</xref>). Different degrees of abnormal glucose tolerance and elevated fasting blood glucose (FBG) have been reported during pregnancy. GDM is a serious life-threatening disease affecting the mother and fetus and its incidence is increasing every year (<xref rid="b2-mmr-0-0-11942" ref-type="bibr">2</xref>) in China. High blood glucose (BG) may increase the incidence of premature delivery and miscarriage. However, the pathogenesis of GDM is still unclear (<xref rid="b2-mmr-0-0-11942" ref-type="bibr">2</xref>). The majority of previous studies have demonstrated that insulin resistance (IR) is one of the key factors involved in the pathogenesis of GDM. In addition, inflammatory factors and oxidative stress also play an important role in this process (<xref rid="b3-mmr-0-0-11942" ref-type="bibr">3</xref>,<xref rid="b4-mmr-0-0-11942" ref-type="bibr">4</xref>). Several studies have reported that the expression levels of antioxidant genes thioredoxin reductase 1 cytoplasmic (TXNRD1) and superoxide dismutase (SOD) are upregulated in type 2 diabetes (<xref rid="b5-mmr-0-0-11942" ref-type="bibr">5</xref>,<xref rid="b6-mmr-0-0-11942" ref-type="bibr">6</xref>).</p>
<p>Moreover, a direct link between GDM and persistent inflammation has been reported in pregnant women (<xref rid="b7-mmr-0-0-11942" ref-type="bibr">7</xref>). Previous studies have also demonstrated that GDM induces abnormal microRNA (miRNA/miR) expression (<xref rid="b8-mmr-0-0-11942" ref-type="bibr">8</xref>,<xref rid="b9-mmr-0-0-11942" ref-type="bibr">9</xref>). miRNAs can be used as diagnostic tools for GDM and may affect the regulation of several cell functions (<xref rid="b10-mmr-0-0-11942" ref-type="bibr">10</xref>). The expression levels of miR-875-5p have been demonstrated to be downregulated in patients with GDM (<xref rid="b11-mmr-0-0-11942" ref-type="bibr">11</xref>). It has also been revealed that miR-875-5p can be used as a biomarker for GDM, suggesting its vital role in the diagnosis of this disease (<xref rid="b11-mmr-0-0-11942" ref-type="bibr">11</xref>). It has also been illustrated that miR-876-5p is involved in the development of cancer and that it can be used for the development of potential novel anticancer therapies (<xref rid="b12-mmr-0-0-11942" ref-type="bibr">12</xref>,<xref rid="b13-mmr-0-0-11942" ref-type="bibr">13</xref>). TXNRD1 gene encodes thioredoxin reductase, and is also known as the TrxR1 gene. TrxR1 is a member of the thioredoxin system, which plays an important role in redox regulation and antioxidant defense by reducing Trx levels in order to maintain the reduction state of intracellular proteins (<xref rid="b14-mmr-0-0-11942" ref-type="bibr">14</xref>). TXNRD1 is predominantly present in the cytoplasm. Cells can fight oxidative stress by upregulating TXNRD1 levels to eliminate hydrogen peroxide and inhibit apoptosis. A previous study indicated that the increase in TXNRD1 levels could play a significant role in treating patients with uncontrolled diabetes (<xref rid="b15-mmr-0-0-11942" ref-type="bibr">15</xref>,<xref rid="b16-mmr-0-0-11942" ref-type="bibr">16</xref>). The TrxR/Trx system plays an important role in the inhibition of oxidative stress, reduction of apoptosis (<xref rid="b17-mmr-0-0-11942" ref-type="bibr">17</xref>), DNA synthesis and the regulation of the NF-&#x03BA;B signaling pathway (<xref rid="b18-mmr-0-0-11942" ref-type="bibr">18</xref>,<xref rid="b19-mmr-0-0-11942" ref-type="bibr">19</xref>). A close association has been demonstrated between the inflammatory response and TXNRD1 (<xref rid="b20-mmr-0-0-11942" ref-type="bibr">20</xref>). Inflammation can regulate TXNRD1 production (<xref rid="b21-mmr-0-0-11942" ref-type="bibr">21</xref>). Therefore, the present study aimed to assess the mechanism of action of miR-875-5p and TXNRD1 in GDM rats.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Animals</title>
<p>A total of 200 Wistar rats (weight, 180&#x2013;270; age, 8 weeks; female, 100, male, 100) were purchased from Junke Biological Co., Ltd. The female rats were fed with normal feed (control group, n=10 rats) or a high fat and high sucrose diet (GDM group, n=90 rats) for 8 weeks at 23&#x2013;25&#x00B0;C with a relative humidity of 65&#x2013;70&#x0025; in a 12 h light/dark cycle. Subsequently, female rats that were in proestrus were caged with males overnight. The rats were identified as pregnant (day 0) according to the observed sperm or mucus plug by microscopy the following day. A total of 100 female rats were identified to be pregnant. The rats in the GDM group were injected intraperitoneally with streptozotocin (35 mg/kg, Sigma-Aldrich; Merck KGaA) to induce gestational diabetes. If the FBG level was stable at 13.5 mmol/l following 24 and 72 h, the GDM rat model was considered to have been successfully established (<xref rid="b22-mmr-0-0-11942" ref-type="bibr">22</xref>). GDM rats were randomly divided into the following groups (n=10 per group): i) GDM group, no treatment; ii) GDM&#x002B;vector group, 4 days following induction, rats were injected with miR-875-5p inhibitor negative control (NC, 10 &#x00B5;M vector) every 3 days via the tail vein; and iii) GDM&#x002B;miR-875-5p inhibitor group, 4 days following induction, rats were injected with miR-875-5p inhibitor (10 &#x00B5;M vector) every 3 days via the tail vein. To further investigate the molecular mechanism of miR-875-5p and TXNRD1, the remaining GDM rats were randomly divided into five groups (n=10 per group): i) GDM, no treatment; ii) GDM&#x002B;sh-NC; iii) GDM&#x002B;sh-TXNRD1; iv) GDM&#x002B;miR-875-5p inhibitor&#x002B;sh-NC (100 &#x00B5;g pGPU6/GFP/Neo-shRNA-NC); and v) GDM&#x002B;miR-875-5p inhibitor&#x002B;sh-TXNRD1 (100 &#x00B5;g pGPU6/GFP/Neo-shTXNRD1). The sequences used for the inhibition of miR-875-5p or TXNRD1 were as follows: miR-875 inhibitor, 5&#x2032;-CACCUGAUAAAACUGAGGUAUA-3&#x2032;; inhibitor NC, 5&#x2032;-AUCGACAGGGUUAACUCCACGA-3&#x2032;; sh-TXNRD1 forward, 5&#x2032;-CACCGCAATGATCTTGAGTTCTATGCGAACATAGAACTCAAGATCATTGC-3&#x2032; and reverse, 5&#x2032;-AAAAGCAATGATCTTGAGTTCTATGTTCGCATAGAACTCAAGATCATTGC-3&#x2032;; shRNA-NC forward, 5&#x2032;-CACCGACATACTCTGTTAGTGTAGTCGAAACTACACTAACAGAGTATGTC-3&#x2032; and reverse, 5&#x2032;-AAAAGACATACTCTGTTAGTGTAGTTTCGCACTACACTAACAGAGTATGTC-3&#x2032;. All sequences were obtained from Guangzhou RiboBio Co., Ltd.</p>
<p>After 7 days, the rats were anesthetized by intraperitoneal injection of 1&#x0025; pentobarbital sodium (50 mg/kg), followed by exsanguination 10 h after fasting. After anesthesia, blood (5 ml) was collected from the abdominal aorta for subsequent experiments. Blood, pancreatic islets and placental tissues of the rats were collected. After the blood samples were collected, they were stored overnight in the refrigerator at 4&#x00B0;C. Subsequently, the serum was collected by centrifugation at 4&#x00B0;C at 1,409 &#x00D7; g for 15 min and divided into 100 &#x00B5;l samples, which were stored at &#x2212;80&#x00B0;C. Other tissues and organs were separated and stored at &#x2212;80&#x00B0;C or fixed in 4&#x0025; formaldehyde solution at room temperature for 48 h. The experimental process is presented in <xref rid="SD1-mmr-0-0-11942" ref-type="supplementary-material">Fig. S1</xref>. All experimental procedures were approved by the Animal Experimental Ethics Committee of The First Hospital of Lanzhou University (approval no. LDYYLL2020-207).</p>
</sec>
<sec>
<title>Reverse transcription-quantitative PCR (RT-qPCR)</title>
<p>Total RNA was extracted using the TRIzol<sup>&#x00AE;</sup> reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer&#x0027;s protocol, and reverse transcribed into cDNA using miScript II RT Kit (Shanghai Beinuo Biotechnology Co., Ltd.) at 37&#x00B0;C for 20 min. miRNA was amplified using the miScript SYBR Green PCR Kit (Shanghai Beinuo Biotechnology Co., Ltd.). The other part of collected serum or pancreatic islet tissues was used to reverse transcribe into cDNA with the PrimeScript RT Reagent Kit (Takara Bio, Inc.) according to the manufacturer&#x0027;s protocol. mRNA was amplified using the SYBR Premix ExTaq (Takara Bio, Inc.). The thermocycling conditions were performed for qPCR as follows: Initial denaturation at 95&#x00B0;C for 3 min, followed by 45 cycles of 95&#x00B0;C for 5 sec, 60&#x00B0;C for 20 sec and 72&#x00B0;C for 15 sec. The Cq value of the target gene of each sample was normalized against U6 or GADPH, and the relative expression levels were measured using the 2<sup>&#x2212;&#x0394;&#x0394;Cq</sup> method (<xref rid="b23-mmr-0-0-11942" ref-type="bibr">23</xref>). The primer sequences used were as follows: miR-875-5p forward, 5&#x2032;-TATACCTCAGTTTTATCAGGTG-3&#x2032; and reverse, 5&#x2032;-GCGGCCGCGTGCATAGCTTCTGTAAAGG-3&#x2032;; TXNRD1 forward, 5&#x2032;-CTTCCACGTACTGGGTCCAAATG-3&#x2032; and reverse, 5&#x2032;-TCACCGACAGCGTTGTAAATATCTC-3&#x2032;; CRP forward, 5&#x2032;-CATCTGTGCCACCTGGGAGTC-3&#x2032; and reverse, AAGCCACCGCCATACGAGTC-3&#x2032;; TNF-&#x03B1; forward, 5&#x2032;-TGAGCACAGAAAGCATGATC-3&#x2032; and reverse, 5&#x2032;-CATCTGCTGGTACCACCAGTT-3&#x2032;; IL-6 forward, 5&#x2032;-GGCCCTTGCTTTCTCTTCG-3&#x2032; and reverse, 5&#x2032;-ATAATAAAGTTTTGATTATGT-3&#x2032;; U6 forward, 5&#x2032;-CTCGCTTCGGCAGCACA-3&#x2032; and reverse, 5&#x2032;-AACGCTTCACGAATTTGCGT-3&#x2032;; and GADPH forward, 5&#x2032;-TCACCATCTTCCAGGAGCGA-3&#x2032; and reverse, 5&#x2032;- ACGCCAGTAGACTCCACG ACA-3&#x2032;.</p>
</sec>
<sec>
<title>Detection of FBG, serum fasting insulin (FINS), homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), triglyceride (TG) and high-density lipoprotein (HDL) levels</title>
<p>Following fasting for 10 h, the blood samples of the rats in each group were collected from the abdominal aorta (5 ml). The blood samples were placed on blood glucose test strips to record FBG levels (Nova Biomedical Corporation). The detection of FINS was performed by enzyme linked immunosorbent assay (cat. no. hzA448Ra; Shanghai Huzhen Biological Technology Co., Ltd.). The HOMA-IR was calculated using the following formula: [FBG (mmol/l) &#x00D7; FINS (mU/l)] / 22.5. TG and HDL levels were determined by an BK-400 automatic biochemical analyzer (BioBase).</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Total protein was isolated from pancreatic islet tissue using RIPA lysis buffer (Sigma-Aldrich; Merck KGaA). The concentration of total protein of the pancreatic islet tissue was determined using the Bradford method. Proteins (50 &#x00B5;g) were separated via SDS-PAGE on a 10&#x0025; gel, and then transferred to PVDF membranes, which were blocked using 5&#x0025; skimmed milk powder for 1 h at 4&#x00B0;C. The membranes were incubated with the following primary antibodies for 2 h at room temperature: Anti-C reactive protein (CRP; cat. no. ab207756; 1:1,000), TNF-&#x03B1; (cat. no. ab205587; 1:1,000), IL-6 (cat. no. ab208113; 1:1,000), TXNRD1 (cat. no. ab124954; 1:1,000) and GAPDH (cat. no. ab9485; 1:1,000) (all purchased from Abcam). Subsequently, membranes were incubated with the HRP-conjugated secondary antibody (cat. no. ab7090; 1:10,000; Abcam) for 1 h at room temperature. Chemiluminescence enhancement reagent (Thermo Fisher Scientific, Inc.) was added to react with the protein band at room temperature for 1 min. The results were analyzed using the ImageJ software (version 1.46r; National Institutes of Health).</p>
</sec>
<sec>
<title>Oxidative stress</title>
<p>Following blood collection, the pancreatic tissues were removed, cut into pieces and further homogenized. Following centrifugation at 1,917 &#x00D7; g for 5 min at 4&#x00B0;C, the supernatant was obtained. The activity of SOD and catalase (CAT), and the content of malondialdehyde (MDA) in the pancreatic tissues were determined by UV-visible spectrophotometry using assay kits (SOD, cat. no. S0086; CAT, cat. no. S0082; MDA, cat. no. S0131S; all purchased from Beyotime Institute of Biotechnology), according to the manufacturer&#x0027;s instructions. The OD value of each group was detected at 560, 405 or 532 nm for SOD activity, CAT activity and MDA content, respectively.</p>
</sec>
<sec>
<title>Hematoxylin and eosin (H&#x0026;E) staining</title>
<p>Following anesthesia of the animals with 1&#x0025; sodium pentobarbital (50 mg/kg, abdominal injection), pancreatic and placental tissues were obtained. The tissues were fixed in 4&#x0025; formaldehyde solution at room temperature for 48 h, embedded in paraffin (thickness of 5 &#x00B5;m) and stained with H&#x0026;E. Hematoxylin staining was performed for 9 min, followed by eosin staining for 2 min. The pathophysiological changes of the pancreatic and placental tissues were observed by light microscopy (magnification, &#x00D7;200).</p>
</sec>
<sec>
<title>Cell lines and luciferase reporter assay</title>
<p>INS-1 cells (American Type Culture Collection) were cultured in RPMI-1640 medium (containing 11.1 mM glucose; Thermo Fisher Scientific, Inc.), in the presence of 10&#x0025; fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 0.11 g/l sodium pyruvate, 50 &#x00B5;M &#x03B2;-mercaptoethanol, and 1&#x0025; penicillin-streptomycin. The cells were maintained at 37&#x00B0;C with 5&#x0025; CO<sub>2</sub>. Cells were seeded into 96-well plates at a density of 40&#x2013;60&#x0025; and cultured in RPMI-1640 medium without penicillin-streptomycin for 24 h, and subsequently transfected with specific plasmids. miR-875-5p mimic (5&#x2032;-UAUACCUCAGUUUUAUCAGGUG-3&#x2032;; 50 nM; Guangzhou RiboBio Co., Ltd.) or scrambled miR-875-5p (5&#x2032;-AUGCAAGGUCGGGGUAACCUCC-3&#x2032;; 50 nM; Guangzhou RiboBio Co., Ltd.) were transfected into INS-1 cells with Lipofectamine<sup>&#x00AE;</sup> 2000 for 48 h at 37&#x00B0;C (Invitrogen; Thermo Fisher Scientific, Inc.). Then, cells were collected and the expression of miR-875-5p was determined using RT-qPCR. The relationship between miR-875-5p and the 3&#x2032; untranslated region (UTR) of TXNRD1 was predicted using Starbase (<uri xlink:href="http://starbase.sysu.edu.cn/">starbase.sysu.edu.cn/</uri>). The interaction was further confirmed by performing dual-luciferase reporter assays. Mutant (MUT) 3&#x2032;UTR of TRXR1 dual-luciferase reporter vectors (Zeye Bio-Web) were constructed using a Site-directed Mutagenesis Kit (cat. no. B639281; Sangon Biotech Co., Ltd.). Wild-type (WT) or MUT vectors and miR-875-5p mimic or scrambled miR-875-5p were co-transfected into the cells using Lipofectamine<sup>&#x00AE;</sup> 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). At 48 h post-transfection, luciferase activities were detected using a Luciferase Reporter Assay Kit (BioVision, Inc.) and a GloMax<sup>&#x00AE;</sup> Discover Microplate Reader (Promega Corporation). Firefly luciferase activities were normalized to <italic>Renilla</italic> luciferase activities.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Data were analyzed using GraphPad Prism software (version 8; GraphPad Software, Inc.). The data are presented as the mean &#x00B1; SD. The comparisons among different groups were performed using ANOVA followed by Tukey&#x0027;s post hoc test. The unpaired Student&#x0027;s test was performed between two groups. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>miR-875-5p regulates FBG, IR and blood lipid levels in GDM rats</title>
<p>The miR-875-5p expression levels in GDM rats were initially analyzed by RT-qPCR. The results indicated that the serum miR-875-5p levels of GDM rats were significantly decreased compared with those of the control group (<xref rid="f1-mmr-0-0-11942" ref-type="fig">Fig. 1A</xref>). Subsequently, the functions of miR-875-5p were assessed through a series of experiments. miR-875-5p knockdown vectors were injected into GDM rats through the tail vein. Serum miR-875-5p levels were significantly reduced following transfection with the miR-875-5p inhibitor (<xref rid="f1-mmr-0-0-11942" ref-type="fig">Fig. 1B</xref>). Furthermore, the miR-875-5p inhibitor significantly decreased FBG and FINS levels in GDM rats compared with those in the GDM group (<xref rid="f1-mmr-0-0-11942" ref-type="fig">Fig. 1C</xref>). In addition, GDM-induced TC and TG levels were significantly decreased, whereas the level of HDL was increased in the miR-875-5p inhibitor group compared with the GDM group (<xref rid="f1-mmr-0-0-11942" ref-type="fig">Fig. 1D</xref>). The results implied that decreased miR-875-5p expression levels played protective roles in reducing FBG, IR and blood lipid levels in GDM rats.</p>
</sec>
<sec>
<title>miR-875-5p inhibitor reduces inflammation in the pancreatic islet tissues of GDM rats</title>
<p>CRP is a non-specific sensitive indicator of the inflammatory response that is closely associated with IR (<xref rid="b24-mmr-0-0-11942" ref-type="bibr">24</xref>). CRP can inhibit the activity of the insulin receptor tyrosine kinase and induce the phosphorylation reaction of insulin receptor substrates (<xref rid="b25-mmr-0-0-11942" ref-type="bibr">25</xref>). Therefore, the insulin synthesis and secretory mechanism are disrupted, which eventually lead to IR. TNF-&#x03B1; can enhance IR by directly inhibiting the expression of the glucose transporter T4 in adipocytes. IL-6 can reduce the sensitivity of the body to insulin and promote the secretion of growth hormones and glucocorticoids, which result in increased IR and BG levels (<xref rid="b26-mmr-0-0-11942" ref-type="bibr">26</xref>,<xref rid="b27-mmr-0-0-11942" ref-type="bibr">27</xref>). Therefore, the present study analyzed the expression levels of CRP, TNF-&#x03B1; and IL-6 in the pancreatic islet tissues in order to assess the effects of miR-875-5p on inflammation. The results indicated that miR-875-5p inhibition significantly reduced CRP, TNF-&#x03B1; and IL-6 expression levels in GDM rats (<xref rid="f2-mmr-0-0-11942" ref-type="fig">Fig. 2A and B</xref>). The induction of oxidative stress in the pancreatic tissues was evaluated by analysis of SOD, CAT and MDA levels (<xref rid="f2-mmr-0-0-11942" ref-type="fig">Fig. 2C</xref>). The results indicated that the enzyme activity of SOD was significantly increased following suppression of miR-875-5p levels in GDM rats compared with that of the GDM group (<xref rid="f2-mmr-0-0-11942" ref-type="fig">Fig. 2C</xref>). The levels of the anti-oxidative stress marker CAT were also significantly increased, whereas the concentration of MDA was decreased.</p>
</sec>
<sec>
<title>miR-875-5p inhibitor alleviates the pathological damage on the pancreatic and placental tissues of GDM rats</title>
<p>The pancreatic tissue presented normal morphology in the control group, whereas in the GDM group it demonstrated notable pathological changes, accompanied by varying degrees of inflammatory cell infiltration. The islets were markedly atrophic, with a reduced number of cells, sparse distribution and disordered arrangement. Following treatment of the animals with the miR-875-5p inhibitor, the pancreatic tissue lesions were notably decreased (<xref rid="f3-mmr-0-0-11942" ref-type="fig">Fig. 3A</xref>). In the control group, maturation of placental cell differentiation was noted, whereas the distribution was uniform and dense and the size of intercellular space was uniform and regular. The capillary blood vessels were evenly distributed and a large number of red blood cells were observed in the blood vessels. The cells in the placenta of the rats in the GDM group (<xref rid="f3-mmr-0-0-11942" ref-type="fig">Fig. 3B</xref>) were loosely distributed and disordered and the intercellular space was increased. Capillary distribution was reduced and the presence of red blood cells was rare. However, miR-875-5p inhibitor treatment markedly reduced placental injury in GDM rats.</p>
</sec>
<sec>
<title>miR-875-5p regulates the expression levels of TXNRD1</title>
<p>Subsequently, the effects of miR-875-5p on TXNRD1 expression were evaluated. First, the expression of miR-875-5p was determined in INS-1 cells following transfection with a miR-875-5p mimic. A significant increase in the expression of miR-875-5p was observed in INS-1 cells with miR-875-5p mimic (<xref rid="f4-mmr-0-0-11942" ref-type="fig">Fig. 4A</xref>). Compared with the GDM&#x002B;vector group, miR-875-5p inhibitor significantly upregulated the levels of TXNRD1 in the serum of GDM rats (<xref rid="f4-mmr-0-0-11942" ref-type="fig">Fig. 4B</xref>), indicating that miR-875-5p could regulate the expression of TXNRD1 in GDM rats. The StarBase database predicted that miR-875-5p could bind to the 3&#x2032;UTR of TXNRD1, which was further confirmed using a dual-luciferase reporter gene assay. The luciferase activity in the TXNRD1 WT vector co-transfected with miR-875-5p mimic was significantly reduced compared with that of the vector group, whereas no differences were observed in the TXNRD1 MUT vectors co-transfected with miR-875-5p mimic or scrambled miR-875-5p (<xref rid="f4-mmr-0-0-11942" ref-type="fig">Fig. 4C</xref>).</p>
</sec>
<sec>
<title>TXNRD1 inhibitor reverses the effects of miR-875-5p on GDM rats</title>
<p>Cells were transfected with sh-TXNRD1, which significantly suppressed the expression of TXNRD1 in the serum of GDM rats (<xref rid="f5-mmr-0-0-11942" ref-type="fig">Fig. 5A and B</xref>). Transfection with sh-TXNRD1 significantly reversed the effects of miR-875-5p inhibitor on glucose, FINS and HOMA-IR (<xref rid="f5-mmr-0-0-11942" ref-type="fig">Fig. 5C</xref>), inflammatory indicators (CRP, TNF-&#x03B1; and IL-6; <xref rid="f5-mmr-0-0-11942" ref-type="fig">Fig. 5D and E</xref>), and oxidative stress levels (SOD, CAT and MDA; <xref rid="f5-mmr-0-0-11942" ref-type="fig">Fig. 5F</xref>). In addition, TXNRD1 knockdown markedly altered the effects of miR-875-5p inhibitor on pancreatic and placental injury in GDM rats (<xref rid="f6-mmr-0-0-11942" ref-type="fig">Fig. 6A and B</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>GDM is a serious life-threatening disease affecting the mother and fetus that displays an increasing incidence annually in China (<xref rid="b2-mmr-0-0-11942" ref-type="bibr">2</xref>). High BG contributes to an increase in the incidence of premature delivery and abortion (<xref rid="b28-mmr-0-0-11942" ref-type="bibr">28</xref>). The present study indicated that transfection with miR-875-5p inhibitor played protective effects by reducing FBG, IR and blood lipid levels, along with improved pancreatic and placental injury in GDM rats. In addition, the levels of the pro-inflammatory and oxidative stress markers were significantly reduced, which implied that the miR-875-5p inhibitor could reduce inflammation in pancreatic islets and oxidative stress in the liver of GDM rats. The data indicated that the effects of miR-875-5p inhibitor could be significantly reversed by TXNRD1 inhibition. Therefore, TXNRD1 played a protective role in GDM rats. Due to the low expression of miR-875-5p noted in the plasma of GDM rats under normal physiological conditions, the expression of TXNRD1 may be maintained at a relatively low level. However, in GDM, the decreased expression of miR-875-5p alleviates its inhibition to TXNRD1 mRNA, which may be one of the underlying mechanisms for the increased expression of reactive TXNRD1 to exert antioxidation.</p>
<p>TrxR has been demonstrated to play a key role in redox regulation and antioxidant protection and is considered a potential target in managing metabolic syndromes (<xref rid="b29-mmr-0-0-11942" ref-type="bibr">29</xref>). IR is closely associated with reduced oxidative stress in GMD. Oxidative stress is considered to be involved in the induction of IR (<xref rid="b30-mmr-0-0-11942" ref-type="bibr">30</xref>&#x2013;<xref rid="b32-mmr-0-0-11942" ref-type="bibr">32</xref>). Therefore, TrxR1 can decrease IR by suppressing oxidative stress. TrxR is also involved in the regulation of inflammatory factors, cell proliferation, apoptosis and embryonic development (<xref rid="b33-mmr-0-0-11942" ref-type="bibr">33</xref>&#x2013;<xref rid="b36-mmr-0-0-11942" ref-type="bibr">36</xref>). The results indicated that the expression levels of TRXR1 mRNA and protein were significantly increased in GDM rats. The increase in TRXR1 mRNA levels induced by GDM may be caused by upregulation of TrxR enzyme activity, which can activate compensatory antioxidant defense systems of the body to protect cells from ROS-induced damage (<xref rid="b37-mmr-0-0-11942" ref-type="bibr">37</xref>,<xref rid="b38-mmr-0-0-11942" ref-type="bibr">38</xref>). A previous study indicated that increased TrxR activity was positively associated with the upregulation of oxidative stress markers (<xref rid="b39-mmr-0-0-11942" ref-type="bibr">39</xref>). The enhanced activity of the Trx/TrxR system is considered to play protective roles in preventing further complications of diabetes. Trx1 can reduce &#x03B2;-cell damage in non-obese diabetic subjects (<xref rid="b40-mmr-0-0-11942" ref-type="bibr">40</xref>). TrxR exerts anti-oxidative functions mainly by preventing stress-induced oxidative damage (<xref rid="b29-mmr-0-0-11942" ref-type="bibr">29</xref>). Previous studies demonstrated that the transcription factor responsive element and the 3&#x2032;UTR of TRXR1 could regulate its transcriptional activation or translation (<xref rid="b41-mmr-0-0-11942" ref-type="bibr">41</xref>,<xref rid="b42-mmr-0-0-11942" ref-type="bibr">42</xref>). In addition, previous studies have shown that transcription factors, such as nuclear factor erythroid 2-related factor 2 and AP-1 regulate TRXR1 expression. In the present study, bioinformatic prediction and molecular biology experiments confirmed that miR-875-5p can specifically bind to TRXR1 3&#x2032;UTR and inhibit the expression of endogenous TRXR1 at the post-transcriptional level to suppress its translation or induce degradation.</p>
<p>In conlcusion, the present study showed that miR-875-5p regulates IR and inflammation via targeting TXNRD1 in GDM model rats. Thus, these results indicated that miR-875-5p and TXNRD1 could be potential targets for treating GDM.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="SD1-mmr-0-0-11942" content-type="local-data">
<caption>
<title>Supporting Data</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was supported by the Research Fund Project of the First Hospital of Lanzhou University (grant no. ldyyyn2018-59), the Research Fund Project of the Science and Technology Development Guiding Plan of Lanzhou City (grant no. 2019-ZD-38), Construction of Gansu Province Clinical Research Center for Endocrine disease (grant no. 20JR10FA667) and the Special Funds of Science and Technology Development of the Chinese Central Government to Guide Local in 2020 (an innovation platform for improving the prevention and treatment of frequently-occurring diseases in Gansu Province).</p>
</sec>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>Songbo F made substantial contributions to the conception and design of the study, the acquisition, analysis and interpretation of data, the acquisition of funding, the collection of data and general supervision of the research group. Songquan F, XM, XY and JL made substantial contributions to the acquisition, analysis and interpretation of data. SongboF and SongquanF confirm the authenticity of all the raw data. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>All the experimental procedures were approved by the Animal Experimental Ethics Committee of The First Hospital of Lanzhou University.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-mmr-0-0-11942"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzger</surname><given-names>BE</given-names></name><name><surname>Coustan</surname><given-names>DR</given-names></name><collab collab-type="corp-author">The Organizing Committee</collab></person-group><article-title>Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus</article-title><source>Diabetes Care</source><volume>21</volume><supplement>(Suppl 2)</supplement><fpage>B161</fpage><lpage>B167</lpage><year>1998</year><pub-id pub-id-type="pmid">9704245</pub-id></element-citation></ref>
<ref id="b2-mmr-0-0-11942"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johns</surname><given-names>EC</given-names></name><name><surname>Denison</surname><given-names>FC</given-names></name><name><surname>Norman</surname><given-names>JE</given-names></name><name><surname>Reynolds</surname><given-names>RM</given-names></name></person-group><article-title>Gestational Diabetes Mellitus: Mechanisms, Treatment, and Complications</article-title><source>Trends Endocrinol Metab</source><volume>29</volume><fpage>743</fpage><lpage>754</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.tem.2018.09.004</pub-id><pub-id pub-id-type="pmid">30297319</pub-id></element-citation></ref>
<ref id="b3-mmr-0-0-11942"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajifaraji</surname><given-names>M</given-names></name><name><surname>Jahanjou</surname><given-names>F</given-names></name><name><surname>Abbasalizadeh</surname><given-names>F</given-names></name><name><surname>Aghamohammadzadeh</surname><given-names>N</given-names></name><name><surname>Abbasi</surname><given-names>MM</given-names></name><name><surname>Dolatkhah</surname><given-names>N</given-names></name></person-group><article-title>Effect of probiotic supplements in women with gestational diabetes mellitus on inflammation and oxidative stress biomarkers: A randomized clinical trial</article-title><source>Asia Pac J Clin Nutr</source><volume>27</volume><fpage>581</fpage><lpage>591</lpage><year>2018</year><pub-id pub-id-type="pmid">29737805</pub-id></element-citation></ref>
<ref id="b4-mmr-0-0-11942"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name></person-group><article-title>Mangiferin ameliorates gestational diabetes mellitus-induced placental oxidative stress, inflammation and endoplasmic reticulum stress and improves fetal outcomes in mice</article-title><source>Eur J Pharmacol</source><volume>859</volume><fpage>172522</fpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172522</pub-id><pub-id pub-id-type="pmid">31276667</pub-id></element-citation></ref>
<ref id="b5-mmr-0-0-11942"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>S</given-names></name><name><surname>Rizi</surname><given-names>EP</given-names></name><name><surname>Shabeer</surname><given-names>M</given-names></name><name><surname>Agrawal</surname><given-names>M</given-names></name></person-group><article-title>Heredity of type 2 diabetes confers increased susceptibility to oxidative stress and inflammation</article-title><source>BMJ Open Diabetes Res Care</source><volume>8</volume><fpage>e000945</fpage><year>2020</year><pub-id pub-id-type="doi">10.1136/bmjdrc-2019-000945</pub-id><pub-id pub-id-type="pmid">32049633</pub-id></element-citation></ref>
<ref id="b6-mmr-0-0-11942"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazem</surname><given-names>MR</given-names></name><name><surname>Asadi</surname><given-names>M</given-names></name><name><surname>Jabbari</surname><given-names>N</given-names></name><name><surname>Allameh</surname><given-names>A</given-names></name></person-group><article-title>Effects of zinc supplementation on superoxide dismutase activity and gene expression, and metabolic parameters in overweight type 2 diabetes patients: A randomized, double-blind, controlled trial</article-title><source>Clin Biochem</source><volume>69</volume><fpage>15</fpage><lpage>20</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2019.05.008</pub-id><pub-id pub-id-type="pmid">31129183</pub-id></element-citation></ref>
<ref id="b7-mmr-0-0-11942"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudharshana Murthy</surname><given-names>KA</given-names></name><name><surname>Bhandiwada</surname><given-names>A</given-names></name><name><surname>Chandan</surname><given-names>SL</given-names></name><name><surname>Gowda</surname><given-names>SL</given-names></name><name><surname>Sindhusree</surname><given-names>G</given-names></name></person-group><article-title>Evaluation of Oxidative Stress and Proinflammatory Cytokines in Gestational Diabetes Mellitus and Their Correlation with Pregnancy Outcome</article-title><source>Indian J Endocrinol Metab</source><volume>22</volume><fpage>79</fpage><lpage>84</lpage><year>2018</year><pub-id pub-id-type="doi">10.4103/ijem.IJEM_232_16</pub-id><pub-id pub-id-type="pmid">29535942</pub-id></element-citation></ref>
<ref id="b8-mmr-0-0-11942"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>HR</given-names></name><name><surname>Sharp</surname><given-names>GC</given-names></name><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name></person-group><article-title>Epigenetics and gestational diabetes: a review of epigenetic epidemiology studies and their use to explore epigenetic mediation and improve prediction</article-title><source>Diabetologia</source><volume>62</volume><fpage>2171</fpage><lpage>2178</lpage><year>2019</year><pub-id pub-id-type="doi">10.1007/s00125-019-05011-8</pub-id><pub-id pub-id-type="pmid">31624900</pub-id></element-citation></ref>
<ref id="b9-mmr-0-0-11942"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasu</surname><given-names>S</given-names></name><name><surname>Kumano</surname><given-names>K</given-names></name><name><surname>Darden</surname><given-names>CM</given-names></name><name><surname>Rahman</surname><given-names>I</given-names></name><name><surname>Lawrence</surname><given-names>MC</given-names></name><name><surname>Naziruddin</surname><given-names>B</given-names></name></person-group><article-title>MicroRNA Signatures as Future Biomarkers for Diagnosis of Diabetes States</article-title><source>Cells</source><volume>8</volume><fpage>E1533</fpage><year>2019</year><pub-id pub-id-type="doi">10.3390/cells8121533</pub-id><pub-id pub-id-type="pmid">31795194</pub-id></element-citation></ref>
<ref id="b10-mmr-0-0-11942"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>S</given-names></name></person-group><article-title>miRNA-221 protects islet beta cell function in gestational diabetes mellitus by targeting PAK1</article-title><source>Biochem Biophys Res Commun</source><volume>520</volume><fpage>218</fpage><lpage>224</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.09.139</pub-id></element-citation></ref>
<ref id="b11-mmr-0-0-11942"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamanian Azodi</surname><given-names>M</given-names></name><name><surname>Rezaei-Tavirani</surname><given-names>M</given-names></name><name><surname>Rezaei-Tavirani</surname><given-names>M</given-names></name><name><surname>Robati</surname><given-names>RM</given-names></name></person-group><article-title>Gestational Diabetes Mellitus Regulatory Network Identifies hsa-miR-145-5p and hsa-miR-875-5p as Potential Biomarkers</article-title><source>Int J Endocrinol Metab</source><volume>17</volume><fpage>e86640</fpage><year>2019</year><pub-id pub-id-type="doi">10.5812/ijem.86640</pub-id><pub-id pub-id-type="pmid">31497041</pub-id></element-citation></ref>
<ref id="b12-mmr-0-0-11942"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>G</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Tu</surname><given-names>K</given-names></name></person-group><article-title>MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1</article-title><source>Biomed Pharmacother</source><volume>103</volume><fpage>645</fpage><lpage>652</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.biopha.2018.04.037</pub-id><pub-id pub-id-type="pmid">29679906</pub-id></element-citation></ref>
<ref id="b13-mmr-0-0-11942"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Xue</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name></person-group><article-title>Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC)</article-title><source>Oncotarget</source><volume>7</volume><fpage>42225</fpage><lpage>42240</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.9944</pub-id><pub-id pub-id-type="pmid">27302926</pub-id></element-citation></ref>
<ref id="b14-mmr-0-0-11942"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cebula</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>EE</given-names></name><name><surname>Arn&#x00E9;r</surname><given-names>ES</given-names></name></person-group><article-title>TrxR1 as a potent regulator of the Nrf2-Keap1 response system</article-title><source>Antioxid Redox Signal</source><volume>23</volume><fpage>823</fpage><lpage>853</lpage><year>2015</year><pub-id pub-id-type="doi">10.1089/ars.2015.6378</pub-id><pub-id pub-id-type="pmid">26058897</pub-id></element-citation></ref>
<ref id="b15-mmr-0-0-11942"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabuyama</surname><given-names>Y</given-names></name><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Yamaki</surname><given-names>J</given-names></name><name><surname>Homma</surname><given-names>MK</given-names></name><name><surname>Kikuchi</surname><given-names>SI</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name></person-group><article-title>Involvement of thioredoxin reductase 1 in the regulation of redox balance and viability of rheumatoid synovial cells</article-title><source>Biochem Biophys Res Commun</source><volume>367</volume><fpage>491</fpage><lpage>496</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.12.178</pub-id><pub-id pub-id-type="pmid">18187038</pub-id></element-citation></ref>
<ref id="b16-mmr-0-0-11942"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Bae</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name></person-group><article-title>CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes</article-title><source>PLoS One</source><volume>13</volume><fpage>e0206152</fpage><year>2018</year><pub-id pub-id-type="doi">10.1371/journal.pone.0206152</pub-id><pub-id pub-id-type="pmid">30365523</pub-id></element-citation></ref>
<ref id="b17-mmr-0-0-11942"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>HR</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Son</surname><given-names>GW</given-names></name><name><surname>Jin</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name></person-group><article-title>Induction of Thioredoxin Reductase 1 by Korean Red Ginseng Water Extract Regulates Cytoprotective Effects on Human Endothelial Cells</article-title><source>Evid Based Complement Alternat Med</source><volume>2015</volume><fpage>972040</fpage><year>2015</year><pub-id pub-id-type="doi">10.1155/2015/972040</pub-id><pub-id pub-id-type="pmid">26236385</pub-id></element-citation></ref>
<ref id="b18-mmr-0-0-11942"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raninga</surname><given-names>PV</given-names></name><name><surname>Di Trapani</surname><given-names>G</given-names></name><name><surname>Vuckovic</surname><given-names>S</given-names></name><name><surname>Tonissen</surname><given-names>KF</given-names></name></person-group><article-title>TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-&#x043A;&#x03B2; inhibition</article-title><source>Cell Cycle</source><volume>15</volume><fpage>559</fpage><lpage>572</lpage><year>2016</year><pub-id pub-id-type="doi">10.1080/15384101.2015.1136038</pub-id><pub-id pub-id-type="pmid">26743692</pub-id></element-citation></ref>
<ref id="b19-mmr-0-0-11942"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname><given-names>M</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Oshima</surname><given-names>H</given-names></name><name><surname>Takaku</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Yodoi</surname><given-names>J</given-names></name><name><surname>Taketo</surname><given-names>MM</given-names></name></person-group><article-title>Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene</article-title><source>Dev Biol</source><volume>178</volume><fpage>179</fpage><lpage>185</lpage><year>1996</year><pub-id pub-id-type="doi">10.1006/dbio.1996.0208</pub-id><pub-id pub-id-type="pmid">8812119</pub-id></element-citation></ref>
<ref id="b20-mmr-0-0-11942"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name></person-group><article-title>Selenomethionine relieves inflammation in the chicken trachea caused by LPS though inhibiting the NF-&#x03BA;B pathway</article-title><source>Biol Trace Elem Res</source><volume>194</volume><fpage>525</fpage><lpage>535</lpage><year>2020</year><pub-id pub-id-type="doi">10.1007/s12011-019-01789-1</pub-id><pub-id pub-id-type="pmid">31325027</pub-id></element-citation></ref>
<ref id="b21-mmr-0-0-11942"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname><given-names>S</given-names></name><name><surname>Mengozzi</surname><given-names>M</given-names></name><name><surname>Heikal</surname><given-names>L</given-names></name><name><surname>Mullen</surname><given-names>L</given-names></name><name><surname>Ghezzi</surname><given-names>P</given-names></name></person-group><article-title>Inflammation-induced reactive nitrogen species cause proteasomal degradation of dimeric peroxiredoxin-1 in a mouse macrophage cell line</article-title><source>Free Radic Res</source><volume>53</volume><fpage>875</fpage><lpage>881</lpage><year>2019</year><pub-id pub-id-type="doi">10.1080/10715762.2019.1637863</pub-id><pub-id pub-id-type="pmid">31257950</pub-id></element-citation></ref>
<ref id="b22-mmr-0-0-11942"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>CM</given-names></name><name><surname>Ramasamy</surname><given-names>R</given-names></name><name><surname>Al Naqeeb</surname><given-names>G</given-names></name><name><surname>Al-Nuaimi</surname><given-names>AH</given-names></name><name><surname>Adam</surname><given-names>A</given-names></name></person-group><article-title>Nicotinamide supplementation protects gestational diabetic rats by reducing oxidative stress and enhancing immune responses</article-title><source>Curr Med Chem</source><volume>19</volume><fpage>5181</fpage><lpage>5186</lpage><year>2012</year><pub-id pub-id-type="doi">10.2174/092986712803530449</pub-id><pub-id pub-id-type="pmid">23237188</pub-id></element-citation></ref>
<ref id="b23-mmr-0-0-11942"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b24-mmr-0-0-11942"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>RM</given-names></name><name><surname>Sharpe</surname><given-names>MD</given-names></name><name><surname>Jagger</surname><given-names>JE</given-names></name><name><surname>Ellis</surname><given-names>CG</given-names></name><name><surname>Sol&#x00E9;-Viol&#x00E1;n</surname><given-names>J</given-names></name><name><surname>L&#x00F3;pez-Rodr&#x00ED;guez</surname><given-names>M</given-names></name><name><surname>Herrera-Ramos</surname><given-names>E</given-names></name><name><surname>Ru&#x00ED;z-Hern&#x00E1;ndez</surname><given-names>J</given-names></name><name><surname>Border&#x00ED;as</surname><given-names>L</given-names></name><name><surname>Horcajada</surname><given-names>J</given-names></name><etal/></person-group><article-title>36th International Symposium on Intensive Care and Emergency Medicine: Brussels, Belgium. 15&#x2013;18 March 2016</article-title><source>Crit Care</source><volume>20</volume><fpage>94</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s13054-016-1208-6</pub-id><pub-id pub-id-type="pmid">27885969</pub-id></element-citation></ref>
<ref id="b25-mmr-0-0-11942"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>SV</given-names></name><name><surname>Plaisance</surname><given-names>EP</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>EY</given-names></name><name><surname>Mahurin</surname><given-names>AJ</given-names></name><name><surname>Grandjean</surname><given-names>PW</given-names></name><name><surname>Mathews</surname><given-names>ST</given-names></name></person-group><article-title>Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome</article-title><source>Diabetes Metab Res Rev</source><volume>25</volume><fpage>427</fpage><lpage>434</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/dmrr.967</pub-id><pub-id pub-id-type="pmid">19405044</pub-id></element-citation></ref>
<ref id="b26-mmr-0-0-11942"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sk&#x00F3;rzy&#x0144;ska-Dziduszko</surname><given-names>KE</given-names></name><name><surname>Kimber-Trojnar</surname><given-names>&#x017B;</given-names></name><name><surname>Patro-Ma&#x0142;ysza</surname><given-names>J</given-names></name><name><surname>Olszewska</surname><given-names>A</given-names></name><name><surname>Zaborowski</surname><given-names>T</given-names></name><name><surname>Ma&#x0142;ecka-Massalska</surname><given-names>T</given-names></name></person-group><article-title>An Interplay between Obesity and Inflammation in Gestational Diabetes Mellitus</article-title><source>Curr Pharm Biotechnol</source><volume>17</volume><fpage>603</fpage><lpage>613</lpage><year>2016</year><pub-id pub-id-type="doi">10.2174/1389201017666160127105926</pub-id><pub-id pub-id-type="pmid">26813307</pub-id></element-citation></ref>
<ref id="b27-mmr-0-0-11942"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roca-Rodr&#x00ED;guez</surname><given-names>MDM</given-names></name><name><surname>L&#x00F3;pez-Tinoco</surname><given-names>C</given-names></name><name><surname>Fern&#x00E1;ndez-Deudero</surname><given-names>&#x00C1;</given-names></name><name><surname>Murri</surname><given-names>M</given-names></name><name><surname>Garc&#x00ED;a-Palacios</surname><given-names>MV</given-names></name><name><surname>Garc&#x00ED;a-Valero</surname><given-names>MDA</given-names></name><name><surname>Tinahones</surname><given-names>FJ</given-names></name><name><surname>Aguilar-Diosdado</surname><given-names>M</given-names></name></person-group><article-title>Unfavorable cytokine and adhesion molecule profiles during and after pregnancy, in women with gestational diabetes mellitus</article-title><source>Endocrinol Diabetes Nutr</source><volume>64</volume><fpage>18</fpage><lpage>25</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.endinu.2016.10.003</pub-id><pub-id pub-id-type="pmid">28440766</pub-id></element-citation></ref>
<ref id="b28-mmr-0-0-11942"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poston</surname><given-names>L</given-names></name><name><surname>Caleyachetty</surname><given-names>R</given-names></name><name><surname>Cnattingius</surname><given-names>S</given-names></name><name><surname>Corval&#x00E1;n</surname><given-names>C</given-names></name><name><surname>Uauy</surname><given-names>R</given-names></name><name><surname>Herring</surname><given-names>S</given-names></name><name><surname>Gillman</surname><given-names>MW</given-names></name></person-group><article-title>Preconceptional and maternal obesity: epidemiology and health consequences</article-title><source>Lancet Diabetes Endocrinol</source><volume>12</volume><fpage>1025</fpage><lpage>1036</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/S2213-8587(16)30217-0</pub-id></element-citation></ref>
<ref id="b29-mmr-0-0-11942"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tinkov</surname><given-names>AA</given-names></name><name><surname>Bj&#x00F8;rklund</surname><given-names>G</given-names></name><name><surname>Skalny</surname><given-names>AV</given-names></name><name><surname>Holmgren</surname><given-names>A</given-names></name><name><surname>Skalnaya</surname><given-names>MG</given-names></name><name><surname>Chirumbolo</surname><given-names>S</given-names></name><name><surname>Aaseth</surname><given-names>J</given-names></name></person-group><article-title>The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: Towards a possible prognostic marker?</article-title><source>Cell Mol Life Sci</source><volume>75</volume><fpage>1567</fpage><lpage>1586</lpage><year>2018</year><pub-id pub-id-type="doi">10.1007/s00018-018-2745-8</pub-id><pub-id pub-id-type="pmid">29327078</pub-id></element-citation></ref>
<ref id="b30-mmr-0-0-11942"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Qu</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name></person-group><article-title>Stress adaptation is associated with insulin resistance in women with gestational diabetes mellitus</article-title><source>Nutr Diab</source><volume>10</volume><fpage>4</fpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s41387-020-0107-8</pub-id></element-citation></ref>
<ref id="b31-mmr-0-0-11942"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueangdetnarong</surname><given-names>H</given-names></name><name><surname>Sekararithi</surname><given-names>R</given-names></name><name><surname>Jaiwongkam</surname><given-names>T</given-names></name><name><surname>Kumfu</surname><given-names>S</given-names></name><name><surname>Chattipakorn</surname><given-names>N</given-names></name><name><surname>Tongsong</surname><given-names>T</given-names></name><name><surname>Jatavan</surname><given-names>P</given-names></name></person-group><article-title>Comparisons of the oxidative stress biomarkers levels in gestational diabetes mellitus (GDM) and non-GDM among Thai population: cohort study</article-title><source>Endocrine Connect</source><volume>7</volume><fpage>681</fpage><lpage>687</lpage><year>2018</year><pub-id pub-id-type="doi">10.1530/EC-18-0093</pub-id></element-citation></ref>
<ref id="b32-mmr-0-0-11942"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zygula</surname><given-names>A</given-names></name><name><surname>Kosinski</surname><given-names>P</given-names></name><name><surname>Zwierzchowska</surname><given-names>A</given-names></name><name><surname>Sochacka</surname><given-names>M</given-names></name><name><surname>Wroczynski</surname><given-names>P</given-names></name><name><surname>Makarewicz-Wujec</surname><given-names>M</given-names></name><name><surname>Pietrzak</surname><given-names>B</given-names></name><name><surname>Wielgos</surname><given-names>M</given-names></name><name><surname>Rzentala</surname><given-names>M</given-names></name><name><surname>Giebultowicz</surname><given-names>J</given-names></name></person-group><article-title>Oxidative stress markers in saliva and plasma differ between diet-controlled and insulin-controlled gestational diabetes mellitus</article-title><source>Diabetes Res Clin Pract</source><volume>148</volume><fpage>72</fpage><lpage>80</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.diabres.2018.11.021</pub-id><pub-id pub-id-type="pmid">30529575</pub-id></element-citation></ref>
<ref id="b33-mmr-0-0-11942"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Holmgren</surname><given-names>A</given-names></name></person-group><article-title>Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic</article-title><source>Free Radic Biol Med</source><volume>127</volume><fpage>238</fpage><lpage>247</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2018.05.081</pub-id><pub-id pub-id-type="pmid">29807162</pub-id></element-citation></ref>
<ref id="b34-mmr-0-0-11942"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Holmgren</surname><given-names>A</given-names></name></person-group><article-title>The thioredoxin antioxidant system</article-title><source>Free Radic Biol Med</source><volume>66</volume><fpage>75</fpage><lpage>87</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.07.036</pub-id><pub-id pub-id-type="pmid">23899494</pub-id></element-citation></ref>
<ref id="b35-mmr-0-0-11942"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arn&#x00E9;r</surname><given-names>ESJ</given-names></name></person-group><article-title>Focus on mammalian thioredoxin reductases - Important selenoproteins with versatile functions</article-title><source>Biochim Biophys Acta</source><volume>1790</volume><fpage>495</fpage><lpage>526</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.bbagen.2009.01.014</pub-id><pub-id pub-id-type="pmid">19364476</pub-id></element-citation></ref>
<ref id="b36-mmr-0-0-11942"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobba</surname><given-names>A</given-names></name><name><surname>Casalino</surname><given-names>E</given-names></name><name><surname>Petragallo</surname><given-names>VA</given-names></name><name><surname>Atlante</surname><given-names>A</given-names></name></person-group><article-title>Thioredoxin/thioredoxin reductase system involvement in cerebellar granule cell apoptosis</article-title><source>Apoptosis</source><volume>19</volume><fpage>1497</fpage><lpage>1508</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s10495-014-1023-y</pub-id><pub-id pub-id-type="pmid">25055978</pub-id></element-citation></ref>
<ref id="b37-mmr-0-0-11942"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>QA</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zappacosta</surname><given-names>F</given-names></name><name><surname>Jeang</surname><given-names>KT</given-names></name><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Hatfield</surname><given-names>DL</given-names></name><name><surname>Gladyshev</surname><given-names>VN</given-names></name></person-group><article-title>Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases</article-title><source>J Biol Chem</source><volume>274</volume><fpage>24522</fpage><lpage>24530</lpage><year>1999</year><pub-id pub-id-type="doi">10.1074/jbc.274.35.24522</pub-id><pub-id pub-id-type="pmid">10455115</pub-id></element-citation></ref>
<ref id="b38-mmr-0-0-11942"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Farrar</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><article-title>Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species</article-title><source>Cell Physiol Biochem</source><volume>44</volume><fpage>532</fpage><lpage>553</lpage><year>2017</year><pub-id pub-id-type="doi">10.1159/000485089</pub-id><pub-id pub-id-type="pmid">29145191</pub-id></element-citation></ref>
<ref id="b39-mmr-0-0-11942"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>V</given-names></name><name><surname>Mancuso</surname><given-names>C</given-names></name><name><surname>Sapienza</surname><given-names>M</given-names></name><name><surname>Puleo</surname><given-names>E</given-names></name><name><surname>Calafato</surname><given-names>S</given-names></name><name><surname>Cornelius</surname><given-names>C</given-names></name><name><surname>Finocchiaro</surname><given-names>M</given-names></name><name><surname>Mangiameli</surname><given-names>A</given-names></name><name><surname>Di Mauro</surname><given-names>M</given-names></name><name><surname>Stella</surname><given-names>AM</given-names></name><name><surname>Castellino</surname><given-names>P</given-names></name></person-group><article-title>Oxidative stress and cellular stress response in diabetic nephropathy</article-title><source>Cell Stress Chaperones</source><volume>12</volume><fpage>299</fpage><lpage>306</lpage><year>2007</year><pub-id pub-id-type="doi">10.1379/CSC-270.1</pub-id><pub-id pub-id-type="pmid">18229449</pub-id></element-citation></ref>
<ref id="b40-mmr-0-0-11942"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chernatynskaya</surname><given-names>AV</given-names></name><name><surname>Looney</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>CQ</given-names></name></person-group><article-title>Administration of recombinant human thioredoxin-1 significantly delays and prevents autoimmune diabetes in nonobese diabetic mice through modulation of autoimmunity</article-title><source>Diabetes Metab Res Rev</source><volume>27</volume><fpage>809</fpage><lpage>812</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/dmrr.1232</pub-id><pub-id pub-id-type="pmid">22069264</pub-id></element-citation></ref>
<ref id="b41-mmr-0-0-11942"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasdaska</surname><given-names>JR</given-names></name><name><surname>Harney</surname><given-names>JW</given-names></name><name><surname>Gasdaska</surname><given-names>PY</given-names></name><name><surname>Powis</surname><given-names>G</given-names></name><name><surname>Berry</surname><given-names>MJ</given-names></name></person-group><article-title>Regulation of Human Thioredoxin Reductase Expression and Activity by 3&#x2032;-Untranslated Region Selenocysteine Insertion Sequence and mRNA Instability Elements</article-title><source>J Biol Chem</source><volume>274</volume><fpage>25379</fpage><lpage>25385</lpage><year>1999</year><pub-id pub-id-type="doi">10.1074/jbc.274.36.25379</pub-id><pub-id pub-id-type="pmid">10464265</pub-id></element-citation></ref>
<ref id="b42-mmr-0-0-11942"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rundl&#x00F6;f</surname><given-names>AK</given-names></name><name><surname>Carlsten</surname><given-names>M</given-names></name><name><surname>Arn&#x00E9;r</surname><given-names>ESJ</given-names></name></person-group><article-title>The core promoter of human thioredoxin reductase 1: Cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich element-regulated gene</article-title><source>J Biol Chem</source><volume>276</volume><fpage>30542</fpage><lpage>30551</lpage><year>2001</year><pub-id pub-id-type="doi">10.1074/jbc.M101452200</pub-id><pub-id pub-id-type="pmid">11375392</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-0-0-11942" position="float">
<label>Figure 1.</label>
<caption><p>miR-875-5p knockdown reduces FBG, IR and blood lipid levels in GDM rats. (A) miR-875-5p levels in serum were significantly reduced in GDM rats, as determined by RT-qPCR. (B) Transfection with miR-875-5p inhibitor significantly reduced miR-875-5p expression in the serum of rats, as analyzed by RT-qPCR. (C) miR-875-5p inhibitor significantly reduced FBG, FINS and HOMA-IR blood levels. (D) Blood lipids levels were significantly affected by transfection with the miR-875-5p inhibitor. n=10, data are presented as the mean &#x00B1; SD. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001. miR, microRNA; GDM, gestational diabetes mellitus; RT-qPCR, reverse transcription-quantitative PCR; FBG, fasting blood glucose; FINS, serum fasting insulin; HOMA-IR, homeostatic model assessment of insulin resistance; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein.</p></caption>
<graphic xlink:href="mmr-23-05-11942-g00.tif"/>
</fig>
<fig id="f2-mmr-0-0-11942" position="float">
<label>Figure 2.</label>
<caption><p>miR-875-5p inhibitor significantly reduces the levels of inflammatory markers and alters the levels of oxidative stress mediator. (A) Transfection with miR-875-5p inhibitor significantly reduced the protein expression of pro-inflammatory markers in the pancreatic islet tissues, as determined by western blotting. (B) Transfection with miR-875-5p inhibitor significantly reduced the mRNA expression of pro-inflammatory markers in the pancreatic islet tissues, as determined by reverse transcription-quantitative PCR. (C) Levels of oxidative stress markers were significantly altered following transfection with miR-875-5p inhibitor. n=10, data are presented as the mean &#x00B1; SD. &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001. miR, microRNA; GDM, gestational diabetes mellitus; CRP, C reactive protein; SOD, superoxide dismutase; CAT, catalase; MDA, malondialdehyde.</p></caption>
<graphic xlink:href="mmr-23-05-11942-g01.tif"/>
</fig>
<fig id="f3-mmr-0-0-11942" position="float">
<label>Figure 3.</label>
<caption><p>miR-875-5p knockdown ameliorates pancreas and placenta injury. (A) Transfection with miR-875-5p inhibitor notably improved pancreatic tissue injury in GDM rats. Arrows indicate islet cells. (B) Transfection with miR-875-5p inhibitor notably improved placental tissue injury in GDM rats. Arrows indicate blood vessels and red blood cells. n=10. miR, microRNA; GDM, gestational diabetes mellitus.</p></caption>
<graphic xlink:href="mmr-23-05-11942-g02.tif"/>
</fig>
<fig id="f4-mmr-0-0-11942" position="float">
<label>Figure 4.</label>
<caption><p>miR-875-5p knockdown upregulates the transcription and translation levels of TXNRD1. (A) Following transfection of INS-1 cells with miR-875-5p mimic, miR-875-5p expression significantly increased. (B) Transfection with miR-875-5p inhibitor significantly increased the TXNRD1 expression in the serum of GDM rats. (C) StarBase was used to predict that miR-875-5p can bind to the 3&#x2032; untranslated region of TXNRD1, and the luciferase activity was significantly reduced by transfection with the miR-875-5p mimic in the WT group. n=10, data are presented as the mean &#x00B1; SD. &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. miR-875-5p-NC. miR, microRNA; GDM, gestational diabetes mellitus; TXNRD1, thioredoxin reductase 1 cytoplasmic; WT, wild-type; MUT, mutant; NC, negative control.</p></caption>
<graphic xlink:href="mmr-23-05-11942-g03.tif"/>
</fig>
<fig id="f5-mmr-0-0-11942" position="float">
<label>Figure 5.</label>
<caption><p>TXNRD1 knockdown reverses the effects of miR-875-5p inhibitor. (A and B) Transfection with sh-TXNRD1 suppressed the expression of TXNRD1 in the serum of GDM rats. (C) TXNRD1 knockdown increased FBG and IR in the blood of GDM rats. (D and E) TXNRD1 knockdown increased expression levels of pro-inflammatory markers in the pancreatic islet tissues. (F) Oxidative stress levels in the pancreatic islet tissues were altered by TXNRD1 knockdown. n=10, data are presented as the mean &#x00B1; SD. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001. miR, microRNA; GDM, gestational diabetes mellitus; sh-, short hairpin RNA; TXNRD1, thioredoxin reductase 1 cytoplasmic; FBG, fasting blood glucose; FINS, serum fasting insulin; HOMA-IR, homeostatic model assessment of insulin resistance; CRP, C reactive protein; SOD, superoxide dismutase; CAT, catalase; MDA, malondialdehyde; NC, negative control.</p></caption>
<graphic xlink:href="mmr-23-05-11942-g04.tif"/>
</fig>
<fig id="f6-mmr-0-0-11942" position="float">
<label>Figure 6.</label>
<caption><p>TXNRD1 knockdown reverses the effects of miR-875-5p inhibitor on pancreas and placenta injury. (A) Transfection with miR-875-5p inhibitor notably increased pancreatic injury. Arrows indicate islet cells. (B) Transfection with miR-875-5p inhibitor induced placental injury. Arrows indicate blood vessels and red blood cells. miR, microRNA; GDM, gestational diabetes mellitus; sh-, short hairpin RNA; TXNRD1, thioredoxin reductase 1 cytoplasmic; NC, negative control.</p></caption>
<graphic xlink:href="mmr-23-05-11942-g05.tif"/>
</fig>
</floats-group>
</article>
